Screener
Travere Therapeutics, Inc. TVTX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Assets | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Commitments and Contingencies (See Note 13) | ||
| Stockholders' Equity: | ||
| Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock $0.0001 par value; 200,000,000 shares authorized; 92,403,744, and 90,922,868 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 9 | 9 |
| Additional paid-in capital | 1,609,596 | 1,588,721 |
| Accumulated deficit | (1,509,815) | (1,472,713) |
| Accumulated other comprehensive loss | (1,062) | (1,189) |
| Total stockholders' equity | 98,728 | 114,828 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s common stock?
- Travere Therapeutics, Inc. (TVTX) reported common stock of $9K in Q1 2026.
- How has Travere Therapeutics, Inc.'s common stock changed year-over-year?
- Travere Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from $9K to $9K.
- What is the long-term trend for Travere Therapeutics, Inc.'s common stock?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s common stock has grown at a 12.5% compound annual growth rate (CAGR), from $5K to $9K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Travere Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude